Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance.

摘要

On July 10,2009, the Food and Drug Ad-mmistration (FDA) approved prasugrel for use in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In the pivotal clinical trial on which this decision was based (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 [TRITON-TIMI 38]), prasugrel reduced the primary composite end point of cardiovascular death, nonfatal myocardial infarction (MI), or non-fatal stroke by 19% compared with clopidogrel.